Breaking Down Tianjin Chase Sun Pharmaceutical Co.,Ltd Financial Health: Key Insights for Investors

Founded in 1996, Tianjin Chase Sun Pharmaceutical Co., Ltd. has grown from a Chinese medicine entrant into a vertically integrated health group known for flagship products like the 'Xuebijing' injection and 'Full Composition' formula granules, reporting sales of RMB 3.348 billion in 2015 and total assets of RMB 6.4 billion by early 2016 while building industry clusters spanning raw materials, herbal planting and modernized TCM preparation; today the Shenzhen-listed company (300026.SZ) operates R&D and industrialization platforms including a Tianjin technology transformation center and academician workstation, serves therapeutic areas from immunity to cardiovascular, and monetizes through sales of formula granules, finished drugs, raw materials, medical devices, excipients, health services and smart supply-chain solutions-financially, 2024 revenue stood at 5.78 billion CNY (down 5.34% YoY) with net income of 21.47 million CNY (down 95.76% YoY), a market capitalization of CN¥11.93 billion as of July 1, 2025, and analyst forecasts projecting strong earnings and revenue growth of 54.4% and 11.7% per annum respectively, underscoring its strategic focus on independent IP, innovation alliances and a diversified, growth-oriented business model

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ): Intro

• Founded: 1996 - entry into China's pharmaceutical sector.
• Listed: Shenzhen Stock Exchange, ticker 300026.SZ (public ownership: institutional + retail investors).
• Strategic positioning: integration of TCM heritage with modern pharmaceutical technology.

• 2015: Achieved sales revenue of RMB 3.348 billion, reflecting significant commercial traction in TCM and pharmaceutical markets.
• Early 2016: Reported total assets of RMB 6.4 billion and a market capitalization near RMB 20 billion, indicating rapid expansion and investor valuation.
• Post‑2016 - 2025: Built industry clusters across raw materials production, Chinese herbal medicine planting and modernized TCM preparation; continues to operate as a high‑tech medicine and health industry group as of 2025.

• Key branded products: "Xuebijing" injection (widely used TCM injectable for sepsis/critical care contexts) and "Full Composition" formula granules for standardized TCM dosing.
• Product ecosystem: injections, granules, chemical APIs and finished dosage forms tied to clinical and retail channels.
• R&D focus: standardization, modern preparation techniques for TCM, and downstream formulation technologies.

• Vertical integration: from herbal planting and raw material production to API/finished‑dose manufacture and distribution.
• Revenue channels:
  • Domestic hospital and clinical sales (prescription TCM injections and hospital consumables).
  • Retail and pharmacy channels for over‑the‑counter TCM granules and packaged formulas.
  • Bulk/API sales and contract manufacturing for third parties.
  • Licensing, technology transfer and potential export of standardized TCM products.
• Cost structure drivers: raw herb cultivation and procurement, GMP manufacturing, R&D and regulatory compliance, sales & distribution.

• Corporate form: publicly traded company with a board and executive management overseeing R&D, manufacturing and commercial operations.
• Investor base: mix of institutional and retail shareholders typical for Shenzhen‑listed mid/large caps; strategic partners include supply‑chain and distribution entities in the TCM ecosystem.
• Competitive edge: combination of proprietary TCM formulations (e.g., Xuebijing), integrated supply chain from planting to finished product, and investments in modernization of TCM preparation.

• Herbal planting bases to secure raw materials, reducing supply risk and controlling quality.
• Raw material / API production clusters enhancing margin capture versus pure contract manufacturing.
• Modernized TCM preparation centers for consistent granules, injections and finished forms meeting GMP standards.

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - History

• Listing: Listed on the Shenzhen Stock Exchange under ticker 300026.SZ.
• Business trajectory: Expanded from chemical intermediates into APIs and finished dosage forms, with increasing focus on regulated production and quality accreditation.
• Governance: Board-led management with roles for operational and financial oversight to guide strategy and compliance in a regulated industry.

• Shareholder access: Detailed shareholder filings and announcements available via the Shenzhen Stock Exchange and the company's investor relations communications.
• Governance purpose: Structure designed to balance strategic decision-making, regulatory compliance and fiduciary oversight across executive management and the board.

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ): Ownership Structure

• Founded from Tianjin traditional Chinese medicine (TCM) heritage, Tianjin Chase Sun has evolved into an integrated pharma group combining R&D, production, investment and sales.
• Corporate mission: to be the inheritor of Chinese medicine and the leader of the health industry, focusing on product lines with independent intellectual property (IP) such as Xuebijing injection and Full Composition formula granules.
• Core values: all‑round innovation, IP ownership, collaborative research alliances, and building industry clusters spanning raw materials, standardized herb planting and modernized TCM preparation.

• Therapeutic priorities: immunity, cardiovascular & cerebrovascular disease, respiratory system, and neurodegenerative diseases.
• Business model: vertical integration from medicinal herb cultivation and raw material manufacture to proprietary formulation development, large‑scale GMP production and multi‑channel distribution (hospital, retail, institutional procurement and export).
• Innovation partnerships: formal alliances with universities and research institutes; corporate R&D teams plus collaborative projects with enterprises as cores of innovation clusters.

• Proprietary products with strong hospital demand - notably Xuebijing injection, licensed for critical care and sepsis-adjunct therapy, contribute a material share of hospital sales.
• Granular proprietary TCM formulas and Chinese patent medicines sold through hospital pharmacies, retail pharmacies and e‑commerce channels.
• Raw material and API production (self‑supplied or third‑party sales) and contract manufacturing for other TCM and pharmaceutical firms.
• Investment income and strategic equity holdings in upstream planting and downstream distribution companies as part of cluster buildout.

• Largest shareholder: Tianjin Chase Sun Group (majority/controlling stake historically around one‑third of issued shares).
• Significant institutional and mutual fund holdings (collective institutional ownership commonly exceeds 40-50% on open market listings), with a meaningful free float on the Shenzhen main board (300026.SZ).
• Board oversight emphasizes R&D and IP protection; management remuneration and incentive plans are frequently tied to product approvals and revenue from core TCM product lines.

• Manufacturing: multi‑site GMP production lines for injections, granules and finished dosage forms; cold‑chain and hospital supply capabilities for critical care products.
• Supply chain: proprietary planting bases for key herbs to secure raw material quality and reduce input volatility; integration of upstream APIs for key formulations.
• R&D pipeline: ongoing clinical and real‑world evidence programs for core products (Xuebijing line extensions, cardiovascular and neurodegenerative TCM formulations) and pursuit of additional IP filings.

• Revenue growth has been driven by hospital procurement and expanded product mix; profitability supported by mid‑to‑high margin proprietary formulations versus lower‑margin raw material sales.
• Risk factors for investors include regulatory review cycles for injections, pricing/procurement pressure in hospital tenders, raw material price volatility and competition from other big TCM groups.
• For further investor details and shareholder composition trends see: Exploring Tianjin Chase Sun Pharmaceutical Co.,Ltd Investor Profile: Who's Buying and Why?

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ): Mission and Values

• End-to-end integration: raw material sourcing → formulation & production → distribution & sales
• Technology platforms: a technology transformation center and an academician workstation in Tianjin accelerate technology transfer and process scale-up
• Research ecosystem: formal innovation alliances with universities and institutes bolster preclinical and formulation research
• Product breadth: Chinese medicine formula granules, finished drugs (tablets, capsules, injections), APIs (active pharmaceutical ingredients), medical devices and excipients
• Therapeutic focus: immunity, cardiovascular & cerebrovascular disease, respiratory diseases and neurodegenerative disorders
• Industry clusters: raw materials production bases, Chinese herbal medicine planting zones and modern TCM preparation hubs

• Technology transformation center (Tianjin) and academician workstation: infrastructure for industrialization of laboratory discoveries
• Collaborative alliances: joint projects with scientific research institutions to speed formulation innovation and clinical validation
• Pipeline: mix of generic finished drugs, proprietary TCM formula granules and new preparations derived from collaborative research

• Finished drug sales: branded and generic pharmaceuticals sold through hospital channels, distributors and retail pharmacies
• Chinese medicine formula granules: supply to hospitals, clinics and TCM chains - recurring revenue from chronic-use formulas
• Active pharmaceutical ingredients and excipients: B2B sales to other manufacturers
• Medical devices and related consumables: device sales and service/consumable replenishment
• Research & contract manufacturing: co-development fees and toll-manufacturing contracts with partners

• Vertical integration: margin protection and supply reliability from upstream to downstream
• TCM specialization: proprietary granules and formula know-how create differentiation versus pure generics
• Innovation infrastructure: technology center and academician workstation reduce time-to-market for improved formulations
• Diversified product mix: lowers dependence on any single therapeutic or product class

• Regulatory scrutiny: drug approvals, GMP inspections and pricing controls can affect product launches and margins
• Raw material and agricultural risk: TCM herb yields and quality fluctuations can affect input costs
• Competition: domestic generics and larger pharma players competing on price and hospital formularies

• Expansion of TCM planting bases to secure high-quality herb supply and vertically integrate raw materials
• Upgrading production lines to meet higher GMP standards and expand high-margin finished product capacity
• Partnerships with academic institutions for new formulation development and clinical evidence generation

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - How It Works

• Primary product lines: Chinese medicine formula granules, finished pharmaceuticals (chemical and traditional), active pharmaceutical ingredients (APIs) / raw materials, excipients, and medical devices.
• Service offerings: medical and health services (clinical/health management partnerships), quality control and testing services, and contract manufacturing.
• Supply-chain solutions: smart logistics, inventory management, procurement platforms and distribution for hospitals, pharmacies and wholesalers.

• Direct product sales to hospitals, pharmacies and distributors (largest revenue contributor).
• Contract manufacturing and OEM supply agreements for domestic and international clients.
• Medical and health service fees from partnerships and clinical support services.
• Value-added supply-chain services (software-enabled logistics, cold-chain, inventory financing) generating recurring service fees and margin uplift.

• Margin pressure from pricing competition in generics and increased input costs for APIs and raw materials.
• Investment in digitalized supply-chain capabilities to reduce distribution costs and create new service revenue streams.
• R&D and registration costs for new formulations and medical devices impacting short-term net income but aimed at long-term growth.

• Upselling integrated service packages (products + logistics + clinical support) to hospital networks.
• Expanding Chinese medicine formula granules market share via standardized production and distribution agreements.
• Scaling smart supply-chain solutions as a platform offering to third parties for recurring revenue.

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ): How It Makes Money

• Market capitalization: CN¥11.93 billion (as of July 1, 2025).
• Analyst forecasts: earnings growth +54.4% p.a.; revenue growth +11.7% p.a.
• Core therapeutic focuses: immunity, cardiovascular & cerebrovascular, respiratory, neurodegenerative diseases.
• Competitive advantages: independent IP for innovative products and vertically integrated industry clusters (APIs, formulations, herbal planting).

• How revenues arise: proprietary drug launches and licensed products drive higher-margin sales; large-volume API and generic production supply steady, lower-margin cash flow; TCM planting and processing secure raw-material cost and quality control; medical services and supply-chain tech add recurring service fees and platform revenue.
• Future monetization levers: commercialization of IP-rich pipelines, scale-up of smart logistics services, and expansion of industry-cluster synergies to compress costs and boost margins.